Frontiers in Molecular Biosciences (Aug 2022)

Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid

  • Giusy Ferraro,
  • Giusy Ferraro,
  • Raffaella Belvedere,
  • Antonello Petrella,
  • Alessandra Tosco,
  • Björn Stork,
  • Stefano Salamone,
  • Stefano Salamone,
  • Alberto Minassi,
  • Alberto Minassi,
  • Federica Pollastro,
  • Federica Pollastro,
  • Elva Morretta,
  • Maria Chiara Monti

DOI
https://doi.org/10.3389/fmolb.2022.964295
Journal volume & issue
Vol. 9

Abstract

Read online

Artemetin is a valuable 5-hydroxy-3,6,7,3′,4′-pentamethoxyflavone present in many different medicinal plants with very good oral bioavailability and drug-likeness values, owing to numerous bioactivities, such as anti-inflammatory and anti-cancer ones. Here, a multi-disciplinary plan has been settled and applied for identifying the artemetin target(s) to inspect its mechanism of action, based on drug affinity-responsive target stability and targeted limited proteolysis. Both approaches point to the disclosure of filamins A and B as direct artemetin targets in HeLa cell lysates, also giving detailed insights into the ligand/protein-binding sites. Interestingly, also 8-prenyl-artemetin, which is an artemetin more permeable semisynthetic analog, directly interacts with filamins A and B. Both compounds alter filamin conformation in living HeLa cells with an effect on cytoskeleton disassembly and on the disorganization of the F-actin filaments. Both the natural compound and its derivative are able to block cell migration, expectantly acting on tumor metastasis occurrence and development.

Keywords